G

GSK

Develops medicines, vaccines, and consumer health

Patient Access Manager

Full-TimeUpdated on 10/23/2026
$152.3k - $253.8k/yr+ Annual bonus + Share-based long-term incentive
Mid
Bachelor's, Master's, MBA, PharmD
Lower Manhattan, New York, NY, USA+4 moreMore locations: Durham, NC, USA | Long Island, New York, USA | Upper Manhattan, New York, NY, USA | South St, New York, NY, USA
In PersonField-based role with travel up to 20%, including overnights. Preferred residence is within the assigned territory or 30 miles of its border.
Medical, Clinical & VeterinaryClinical Support & Patient Administration

About the job

Requirements
  • A bachelor's degree is required.
  • At least 3 years of combined experience in field reimbursement, hub case management, patient experience programs, or helping patients and providers navigate insurance verification, prior authorization requirements, and access criteria.
  • Ability to travel up to 20%, including overnight travel.
  • A valid driver's license is required.
  • Candidates should preferably reside within the assigned territory or within 30 miles of its border.
  • Extensive experience in oncology patient navigation, access and reimbursement, or hub case management is preferred.
  • An advanced degree, such as an MBA, MPH, PharmD, or another relevant clinical or business degree, is preferred.
  • An active registered nurse license and Bachelor of Science in Nursing are preferred.
  • Experience using customer relationship management and case-management platforms, preferably Salesforce Health Cloud, to document interactions, manage cases, and maintain accurate records is preferred.
  • Strong verbal, written, and presentation communication skills are preferred.
Responsibilities
  • Serve as the point of contact for patients, caregivers, and healthcare provider office staff, providing approved information and education on oncology-specific care, including benefit discussions, product and disease-state information per the Prescribing Information, and program-specific resources.
  • Conduct welcome calls and ongoing journey touchpoints, discussing the end-to-end patient experience within program specifics and using approved call guides, frequently asked questions, and the Prescribing Information.
  • Support patient enrollment in GSK services, including patient assistance programs, and guide patients and offices through enrollment requirements, missing information, and consent capture.
  • Provide program-specific treatment education via approved call guides, offering the Important Safety Information and Prescribing Information whenever product education is delivered.
  • Educate patients on coverage outcomes, cost-sharing, and financial assistance options, including publicly available information on alternate coverage and independent foundations within program rules.
  • Facilitate transfers to Specialty Pharmacy, Medical Information, the GSK Response Center, Risk Evaluation and Mitigation Strategy vendors, and back-office Benefits Specialists for benefit investigation/benefit verification and prior authorization tracking when appropriate.
  • Conduct all patient communication through approved recorded telephony and program systems, verifying patient identifiers and consent status before each interaction.
  • Maintain accurate documentation of activities and interactions within GSK's internal system.
  • Capture and report adverse events and product quality complaints within required timeframes and follow crisis-management procedures.
  • Adhere to company policies and procedures, compliance guidance, and policies applicable to federal, state, and local regulations.
  • Ensure activities align with Health Insurance Portability and Accountability Act privacy requirements and internal compliance guidelines.
  • Educate provider offices on payer coverage, coding, and payment policies for GSK Oncology products using approved materials, and help offices understand and use GSK Patient Support Programs.
  • Support access case resolution at the office level by explaining benefit investigation outcomes, prior authorization requirements and processes, and appeal pathways; provider offices initiate and submit all payer forms.
  • Identify access and reimbursement barriers and escalate complex, systemic, or technical payer issues to the specialist access function and leadership.
  • Interface with Payer Account Managers, Specialty Pharmacy Account Directors, and Oncology Sales teams within the boundaries of the PAN Standard and program ways of working.
  • Document all interactions and manage cases in Salesforce Health Cloud/customer relationship management systems in line with program standards.
  • Follow all standard operating procedures and business rules consistently, and complete training on corporate policies governing access to confidential data on time.
  • Maintain strict separation between patient-facing and account-facing activity: do not share patient-identifiable information with commercial teams, and never combine the two sides of the role in a single engagement or documentation thread.
  • Operate strictly within approved materials and compliance guardrails.
Desired Qualifications
  • The listed preferred qualifications are captured in the requirements list.

About the company

GSK is a global healthcare company focused on three main areas: Pharmaceuticals, Vaccines, and Consumer Healthcare. It develops medicines, vaccines, and consumer health products to improve health outcomes worldwide. Its products address diseases in respiratory, HIV, oncology, and immuno-inflammatory areas; vaccines for influenza, shingles, and COVID-19; and over-the-counter wellness products. The company relies on substantial R&D and strategic partnerships to bring new products to market and to address health needs. Revenues come from sales of medicines, vaccines, and consumer health items, often complemented by patient support programs and collaborations with governments and biotech partners.

Company Size

10,001+

Company Stage

IPO

Headquarters

London, United Kingdom

Founded

1891

Get referred to GSK

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Luke Miels launched a £1.9 billion savings plan to fund R&D and late-stage development.
  • GSK expects more than £10 billion operating cash flow in 2026, financing acquisitions and launches.
  • Blenrep, Jideytro, and Excentia each have 2026-2027 catalysts that can lift revenue.

What critics are saying

  • Dresden’s 2027 closure cuts 641 jobs and exposes declining demand in legacy flu vaccines.
  • Camlipixant’s failure triggered a £1.3 billion impairment, showing pipeline execution remains fragile.
  • Zantac appeals and a securities case still threaten cash, disclosures, and management focus.

What makes GSK unique

  • GSK’s 62-asset pipeline spans HIV, oncology, vaccines, and respiratory with 20+ Phase III starts in 2026.
  • Jideytro, Blenrep, and Excentia create multiple launch vectors beyond Shingrix.
  • GSK’s vaccine and specialty-medicine manufacturing network supports global scale across regulated markets.

Help us improve and share your feedback! Did you find this helpful?

Benefits

  • Health Insurance
  • 401(k) Retirement Plan
  • Remote Work Options
  • Flexible Work Hours
  • Paid Vacation
  • Paid Holidays
  • Hybrid Work Options
  • Wellness Program
  • Mental Health Support
  • Phone/Internet Stipend

Company News

Yahoo Finance
Oct 23rd, 2026
GSK shares up 20.4% despite 5.2% net margin as $10.6B Nuvalent deal lifts pipeline hopes

GSK shares have risen 20.4% over the past year, including dividends, even as the company's profitability weakened. The stock now trades at £19.14, up from £16.52 at the start of the period. Revenue reached £8,409m, but net income slipped to £435m and net margin fell to 5.2%. GSK agreed to buy Nuvalent for $10.6 billion to deepen its lung cancer pipeline. It also won approvals for Jideytro, Hibsago, and the new antibiotic Utebzi. The bullish case puts fair value at £23.63, assuming 8.5% annual revenue growth and margins rising to 19.8% by 2028. The bearish case puts it at £11.2, citing cost pressure, HIV patent expiries, and pricing and legal risks. GSK plans to fund growth through a £1.9 billion cost-saving programme and site closures.

Associated Press
Oct 21st, 2026
FDA approves GSK's Hibsago, offering 19% functional cure rate for chronic hepatitis B

The US Food and Drug Administration (FDA) has approved GSK's Hibsago (bepirovirsen) for chronic hepatitis B in adults without cirrhosis. It is used alongside nucleos(t)ide analogue therapy in patients with suppressed viral DNA and surface antigen levels of 3,000 IU/ml or below. GSK says it is the first treatment of its kind to offer a potential functional cure after six months. Patients can self-administer after the first dose. In B-Well phase III trials, 19% of patients reached functional cure (233 of 1,220), against none of 614 on placebo. Standard care typically achieves less than 1% after a year. The most common adverse events were injection site redness, local pain, and a temporary rise in a liver enzyme. The label carries a boxed warning for liver flares and low platelet counts. GSK licensed the drug from Ionis. It is also approved in Japan.

Associated Press
Oct 19th, 2026
FDA approves Jemperli as first immunotherapy for MSI-H/dMMR rectal cancer, with 68% response

The US Food and Drug Administration (FDA) has approved GSK's Jemperli (dostarlimab) as the first immunotherapy for adults with stage II and III locally advanced rectal cancer that is microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR). AnaptysBio, which manages the financial collaboration for the drug, announced the approval on October 19, 2026. The decision rests on the AZUR-1 trial. Among evaluable patients, 68% (98 of 144) had a sustained clinical complete response at 12 months, according to investigator assessment. No recurrences have been reported among responders after a median follow-up of more than two years. Jemperli alone could help eligible patients avoid chemotherapy, radiation, and surgery. Serious adverse reactions occurred in 20% of patients. GSK will present full interim data at the ESMO Congress in Madrid on October 25, 2026.

Sharecast
Oct 19th, 2026
GSK's Ris-Rez shows 61pc response rate in early lung cancer study.

GSK's Ris-Rez shows 61pc response rate in early lung cancer study. 1,856.00p. 13:24 19/10/26. Drugmaker GSK reported new early-stage global data for risvutatug rezetecan (Ris-Rez), an experimental cancer treatment being tested in patients with relapsed small-cell lung cancer. 10,747.73. 5,853.07. 5,792.15. 24,009.43. 13:23 19/10/26. In a phase Ib study, GSK said the drug produced a 61% response rate at the higher 8mg/kg dose, compared with 32% at 6mg/kg. GSK said the results, which will be presented at the ESMO 2026 congress in Madrid, support using the 8mg/kg dose in its ongoing global phase III trial. The FTSE 100-listed company said the treatment's side-effect profile was manageable, with most issues linked to blood-related conditions. More serious side effects occurred in 42% of patients at the higher dose and 15% at the lower dose. One case of interstitial lung disease was reported across 50 patients. GSK's Hesham Abdullah said: "Today's first global data for Ris-Rez build on the statistically significant overall survival benefit recently reported in Hansoh's pivotal Chinese trial. As the data for Ris-Rez continues to grow, we remain focused on accelerating development in extensive-stage small cell lung cancer, where patients often relapse quickly and urgently need more treatment options." As of 0905 BST, GSK shares were up 0.16% at 1,865.50p. Reporting by Iain Gilbert at Sharecast.com

Yahoo Finance
Oct 15th, 2026
GSK beats Pfizer as dividend stock: 39% payout vs 89% of free cash flow

GSK looks the better dividend stock than Pfizer, according to a comparison of the two drugmakers, which both face major patent losses before 2030. Pfizer yields 6.3% and GSK 4.1%. Over the twelve months to June 2026, Pfizer paid out 89% of its free cash flow in dividends ($9.79 billion of $10.98 billion), against 39% at GSK (£2.67 billion of £6.90 billion). Pfizer's chief executive officer, Albert Bourla, said the dividend will be maintained even in "the most stretched scenarios." Pfizer raised its 2026 revenue guidance to $60.5 billion to $62.5 billion. GSK raised its dividend 17.6% in fiscal 2025 after an earlier cut, and Q2 2026 sales rose 5%. Its main risk is debt: net debt rose to £22 billion after the Nuvalent acquisition.